NEW YORK (GenomeWeb News) – Laboratory Corporation of America said last week that it will offer Roche’s Cobas TaqMan HBV test.
The test was cleared in September by the US Food and Drug Administration. It uses real-time PCR to quantify the amount of hepatitis B virus DNA in a patient’s blood. It may be used by physicians to determine a baseline level of infection and thereafter as an aid in assessing a patient’s response to therapy.
According to Roche, it is the first hepatitis B viral load test approved for marketing by the FDA.
LabCorp said it would begin offering the test this week.